Latest Impairment News

Page 13 of 49
AVADA Group Limited reported a revenue decline and a $9.7 million impairment on its New Zealand operations in FY25, while completing Phase 1 of its business transformation including ERP implementation and operational consolidation.
Victor Sage
Victor Sage
29 Aug 2025
Locality Planning Energy Holdings reports a 79% rise in group profit excluding impairment, signaling a pivotal transformation as it outlines ambitious FY2026 growth plans.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Locality Planning Energy Holdings reported a modest revenue increase for FY2025 despite a significant impairment charge, as it pivots toward a disciplined, customer-focused multi-utility model.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Linius Technologies reported a $5.31 million loss for FY25 as it shifts towards a sales-driven SaaS model, with new leadership and cost-cutting measures aiming to reshape its future.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Adisyn Ltd reported a sharp increase in losses for FY25, driven by a 40% revenue drop and a costly acquisition, while securing significant new equity funding.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Energy World Corporation Ltd reports a remarkable turnaround to a $346 million profit for FY25, driven by a $390 million gain from debt restructuring and the sale of a key Indonesian asset. The company faces funding challenges as it advances LNG and power projects in Southeast Asia.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.
Ada Torres
Ada Torres
29 Aug 2025
Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.
Victor Sage
Victor Sage
29 Aug 2025
DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.
Claire Turing
Claire Turing
29 Aug 2025
Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.
Ada Torres
Ada Torres
29 Aug 2025
Oliver's Real Food reported a 25.8% increase in net loss to $2.91 million for FY2025 despite a 23.5% rise in core earnings before impairments, driven by operational restructuring and store closures.
Victor Sage
Victor Sage
29 Aug 2025
Saferoads Holdings Limited reported a net profit of $4.35 million for FY2025, driven largely by a $5.27 million gain from the sale of its Road Safety Rental business. Continuing operations showed a modest loss amid a 14% revenue decline.
Victor Sage
Victor Sage
29 Aug 2025